Angiotensin vaccination: What is the prospect of success?

Current Hypertension Reports

Volumn 11, Issue 1, 2009, Pages 63-68

  Campbell, Duncan J ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN I KEYHOLE LIMPET HEMOCYANIN CONJUGATE; ANGIOTENSIN II VACCINE; ANTIIDIOTYPIC ANTIBODY; BIOLOGICAL PRODUCT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KEYHOLE LIMPET HEMOCYANIN; PLACEBO; RENIN; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIHYPERTENSIVE ACTIVITY; AUTOIMMUNE DISEASE; BINDING AFFINITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; DRUG WITHDRAWAL; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYNCOPE; TOOTH PAIN; VACCINE PRODUCTION; VERTIGO;

ANGIOTENSINS; ANIMALS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; VACCINES;

EID: 59149096970     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0012-y     Document Type: Review

References (39)

1. Elliott WJ: The economic impact of hypertension. J Clin Hypertens (Greenwich) 2003, 5:3-13.
2. Burnier M: Long-term compliance with antihyperAensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000, 5(Suppl 1):S31-S34.
3. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectivelydesigned overviews of randomised trials. Lancet 2003, 362: 1527-1535.
4. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
5. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
6. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
7. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
8. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002, 359:995-1003.
10. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
11. Michel J-B, Guettier C, Reade R, et al.: Immunologic approaches to blockade of the renin-angiotensin system: A review. AmHeart J 1989, 117:756-767.
12. Michel JB, Galen FX, Guettier C, et al.: Immunological approach to blockade of the renin-substrate reaction. J Hypertens Suppl 1989, 7:S63-S70.
13. Michel JB: Renin-angiOtensin vaccine: old story, new project 'efficacy versus safety'. Clin Sci (Lond) 2004, 107:145-147.
14. Menard J: A vaccine for hypertension. J Hypertens 2007, 25:41-46.
15. Campbell DJ, Duncan A-M, Kladis A, Harrap SB: Angiotensin peptides in spontaneously hypertensive and normotensive Donryu rats. Hypertension 1995, 25:928-934.
16. Downham MR, Auton TR, Rosul A, et al.: Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 2003, 56: 505-512.
17. Brown MJ, Coltart J, Gunewardena K, et al.: Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107:167-173.
18. Ambühl PM, Tissot AC, Fulurija A, et al.: A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63-72.
19. Tissot AC, Maurer P, Nussberger J, et al.: Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: A double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821-827.
20. Campbell DJ: The site of angiotensin production. J Hypertens 1985, 3:199-207.
21. Wiig H, Gyenge CC, Tenstad O: The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol 2005, 567:557-567.
22. Admiraal PJJ, Derkx FHM, Danser AHJ, et al.: Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 1990, 15:44-55.
23. Maillard MP, Wurzner G, Nussberger J, et al.: Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther 2002, 71:68-76.
24. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril. Hypertension 2002, 39:e1-e8.
25. Admiraal PJJ, Derkx FHM, Danser AHJ, et al.: Intrarenal de novo production of angiotensin I in subjects with renal artery stenosis. Hypertension 1990, 16:555-563.
26. Refetoff S: Inherited thyroxine-binding globulin abnormalities in man. Endocr Rev 1989, 10:275-293.
27. Stockigt J: Assessment of Thyroid function: towards an integrated laboratory-clinical approach. Clin Biochem 2003, 24:109-122.
28. Lacourciere Y, Asmar R: A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: A placebo-controlled, forced titration study. Candesartan/ Losartan study investigators. Am J Hypertens 1999, 12:1181-1187.
29. Coca A, Calvo C, Garcia-Puig J, et al.: A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: The MAPAVEL Study (Monitorizacion Ambulatoria Presion Arterial APROVEL). Clin Ther 2002, 24:126-138.
30. Prichard BN, Jager BA, Luszick JH, et al.: Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press 2002, 11:166-172.
31. Ready T: Blood pressure vaccine shot down by safety concerns. Nat Med 2005, 11:1262.
32. Bachmann MF, Nussberger J, Tissot AC, Jennings GT: Reply to 'Blood pressure vaccine shot down by safety concerns.' Nat Med 2006, 12:270.
33. Samuelsson O, Herlitz H: VaccinatioA against high blood pressure: a new strategy. Lancet 2008, 371:788-789.
34. Shechter Y, Maron R, Elias D, Cohen IR: Autoantibodies to insulin receptor spontaneously develop as anti-idiotypes in mice immunized with insulin. Science 1982, 216:542-545.
35. Batarseh H, Thompson RA, Odugbesan O, Barnett AH: Insulin receptor antibodies in diabetes mellitus. Clinical and experimental immunology 1988, 71:85-90.
36. Couraud PO: Anti-angiotensin II anti-idiotypic antibodies bind to angiotensin II receptor. J Immunol 1987, 138:1164-1168.
37. Xia Y, Ramin SM, Kellems RE: Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007, 50:269-275.
38. Dragun D, Muller DN, Brasen JH, et al.: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
39. Mooser V, Nussberger J, Juillerat L, et al.: Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990, 15:276-282.